Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desensitization Protocol for Highly Sensitized Kidney Transplant Candidates
NCT01502267Phase 2Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Jan 2010
- Primary completion
- Jan 2014
- Modality
- Monoclonal Antibodies, Modified Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of immune globulin, rituximab, bortezomib in Human Leukocyte Antigen Sensitization, sponsored by Seoul National University Hospital. Status: unknown.
02
Drugs
immune globulinrituximabbortezomib
03
Conditions
Human Leukocyte Antigen Sensitization
Beyond the preview
Go deeper on NCT01502267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01502267.